Sarcoma-like tumor originating from oligodendroglioma

Shoji, Taku; Saito, Ryuta; Kanamori, Masayuki; Sonoda, Yukihiko; Watanabe, Mika; Tominaga, Teiji

doi:10.1007/s10014-016-0268-2

Cited by 10 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There has been another reported case of oligosarcoma originating from grade II oligodendroglioma, IDH mutant and 1p/19q codeleted, without any adjuvant therapy. 6 The recurrent tumor retained both genetic characteristics.…”

Section: Discussionmentioning

confidence: 98%

“…The glial component is usually astrocytic, and gliosarcoma, in which the glial component is oligodendroglia, is quite rare. There have been few reports of a sarcomatous tumor arising as oligodendroglioma with 1p/19q codeleted …”

Section: Introductionmentioning

confidence: 99%

“…There have been few reports of a sarcomatous tumor arising as oligodendroglioma with 1p/19q codeleted. [4][5][6] Here, we describe a case of a sarcoma-like tumor that originated from a grade II oligodendroglioma with IDH mutant and 1p/19q codeleted. The recurrent tumor consisted of two distinct components, sarcomatous and oligodendroglial, both of which exhibited the IDH mutation and 1p/19q codeleted.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted

et al. 2017

View full text Add to dashboard Cite

Herein, we present a rare case of gliosarcoma arising from oligodendroglioma, isocitrate dehydrogenase (IDH) mutant and 1p/19q codeleted. A 36-year-old man presented with a non-enhanced calcified abnormal lesion on the right frontal lobe. The patient underwent subtotal surgical resection, PAV chemotherapy (procarbazine, nimustine (ACNU) and vincristine), and fractionated radiotherapy with 50 Gy. The pathological diagnosis was oligodendroglioma, IDH mutant and 1p/19q codeleted, World Health Organization 2016 grade II. Six years later, a new enhanced lesion appeared, and the recurrent tumor was surgically removed. Although the histopathological findings indicated gliosarcoma, the recurrent tumor still demonstrated the IDH mutation and 1p/19q codeleted. Thus, the recurrent tumor was considered to originate from oligodendroglioma, rather than being newly generated after chemoradiotherapy. Interestingly, the second recurrent tumor responded well to temozolomide chemotherapy. Based on the findings of this case, oligodendrogliomas have the potential for mesenchymal transformation on progression, while keeping their genotype.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted

et al. 2017

View full text Add to dashboard Cite

show abstract

“…6 Although in most cases the glial component of the sarcomatous tumors is astrocytic, the literature describes several cases of gliosarcomas in which the glial component is oligodendrocytic. 2,3,[6][7][8][9][10] Here, we describe the case of an oligodendroglioma WHO grade II with 1p/19q co-deletion, IDH-1 and ATRX mutation, with initial GTR, not subjected to complementary treatments, and which was dedifferentiated to the sarcomatous form. The tumor always maintained the same genetic characteristics.…”

Section: Discussionmentioning

confidence: 99%

Oligodendroglioma with Sarcomatous Transformation: Case Report and Literature Review

2019

View full text Add to dashboard Cite

Oligodendrogliomas are infiltrative tumors of the central nervous system considered to be morphologically stable and to offer a better prognosis. Here, we describe the case of a 36-year-old man with an initial diagnosis of oligodendroglioma, World Health Organization (WHO) grade II, who presented transformation to a sarcomatous form, while maintaining the oligodendroglial component as well as the genetic characteristics of the initial tumor without having undergone any complementary treatments previously. Despite the favorable genetic characteristics, the tumor presented poor response to complementary treatments, and rapid progression, including spinal metastasis.

show abstract

“…Rare sarcoma-like tumors originating from oligodendroglioma have been reported, with documented IDH1 mutation and 1p/19q co-deletion, and have been termed "oligosarcoma". 39,40,41 Among all sarcomas with CDKN2C loss, 1p/19q-codeletion appears to be nearly exclusive to LMS. However, in the overall LMS cohort, occasional cases with TP53 and RB1 alterations were positive by the 1p/19q-codeletion detection algorithm.…”

Section: Discussionmentioning

confidence: 99%

CDKN2Chomozygous loss identifies a distinct subtype ofTP53/RB1-wildtype leiomyosarcoma with frequentCICgenomic alterations and 1p/19q-codeletion

Williams¹,

Sharaf²,

Decker

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose Leiomyosarcomas (LMS) harbor frequent inactivation of TP53 and RB1, and extensive DNA copy number alterations. Here, we describe a distinct recurrent genomic signature in TP53/RB1-wildtype uterine LMS.Methods Tissues from 276,645 unique advanced cancers, including 2,570 uterine and soft tissue LMS were sequenced by hybrid-capture-based next-generation DNA and RNA sequencing/comprehensive genomic profiling of up to 406 genes. We characterized clinicopathologic features of relevant cases. ResultsWe identified 77 LMS with homozygous copy loss of CDKN2C at chromosome 1p32.3 (3.0% of LMS). Genomic alterations (GAs) in TP53, RB1, and ATRX were rare in comparison with the remainder of the LMS cohort (11.7% vs 73.4%, 0% vs 54.5%, 2.6% vs 24.5%, all p<0.0001). CDKN2C-null LMS cases were significantly enriched for GAs in CIC (40.3% vs 1.4%) at 19q13.2, CDKN2A (46.8% vs 7.0%), and RAD51B (16.9% vs 1.7%; all p<0.0001). Chromosome arm-level aneuploidy analysis of available LMS cases (n=1,251) found that 85% (n=33/39) of CDKN2C-null LMS cases exhibited 1p/19qcodeletion, with significant enrichment in comparison to the remainder of the evaluated LMS cohort (85% vs. 5.1%, p<0.0001).99% of CDKN2C-null cases were in females; median age was 61 years at surgery (range, 36-81 years). 55 cases were of uterine primary, 4 cases non-uterine, and the remaining 18 of uncertain primary site. 6 patients had a prior history of leiomyomatosis or uterine smooth muscle tumor of uncertain malignant potential. 60% of cases showed at least focal epithelioid variant histology. Most cases were of known advanced stage, with 62% of confirmed uterine primary cases at FIGO stage IVB.

show abstract

Sarcoma-like tumor originating from oligodendroglioma

Cited by 10 publications

References 22 publications

Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted

Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted

Oligodendroglioma with Sarcomatous Transformation: Case Report and Literature Review

CDKN2Chomozygous loss identifies a distinct subtype ofTP53/RB1-wildtype leiomyosarcoma with frequentCICgenomic alterations and 1p/19q-codeletion

Contact Info

Product

Resources

About